Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Driven Brands Holdings Inc. (DRVN)
Get Alerts DRVN Hot Sheet
Join SI Premium – FREE
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Driven Brands Holdings Inc. (“Driven” or the “Company”) (NASDAQ: DRVN) securities between May 9, 2023 and February 24, 2026, inclusive (the “Class Period”).
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose Driven Brands’ financial condition and the effectiveness of its internal controls over financial reporting through a series of inaccurate financial reports filed with the Securities and Exchange Commission (“SEC”) from May 9, 2023, to November 5, 2025. The Complaint alleges that among many other errors, Driven Brands’ balance sheets contained an unreconciled cash balance originating in 2023 which resulted in revenue and cash being overstated in 2023 and 2024, and operating expenses being understated over the same period.
Investors who purchased or otherwise acquired shares of Driven should contact the Firm prior to the May 8, 2026 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
Source: Gainey McKenna & Egleston
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elicio Therapeutics prices $15M registered direct offering
- Meridian3 Industrials prices $175M IPO on Nasdaq
- Telix gets FDA alignment to expand prostate cancer trial to U.S.
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share